Veru Cash and Cash Equivalents Rise to $27.6 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Cash, cash equivalents and restricted cash were $27.6M as of March 31 versus $15.8M as of September 30, 2025. "We are extremely pleased with the progress of the enrollment of the Phase 2b PLATEAU clinical trial to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients who have obesity and receiving a semaglutide GLP-1 RA treatment for weight reduction. We are on track for presenting the results of the interim analysis which is expected in Q1 calendar year 2027," said Mitchell Steiner, Chairman, President, and CEO of Veru.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VERU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VERU
Wall Street analysts forecast VERU stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.250
Low
25.00
Averages
25.00
High
25.00
Current: 2.250
Low
25.00
Averages
25.00
High
25.00
About VERU
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veru Partners with Novo Nordisk for Phase 2b PLATEAU Study
- Clinical Trial Partnership: Veru announced it will sponsor the Phase 2b PLATEAU study, with Novo Nordisk providing Wegovy at no cost, significantly enhancing Veru's market position in obesity treatment.
- Stock Surge: Following the announcement of the clinical supply agreement with Novo Nordisk, Veru's stock soared over 160% in Thursday morning trading, reflecting strong investor confidence in its new drug enobosarm.
- Global Development Rights Retained: Veru stated in a filing with the SEC that it will retain full global development and commercialization rights to enobosarm, laying a solid foundation for future market promotion.
- Market Validation: Canaccord views this partnership as a significant milestone for Veru, indicating strong market interest in enobosarm and anticipating it could emerge as a key differentiator in obesity treatment.
See More
Veru Inc. Q2 Fiscal 2026 Earnings Call Insights
- R&D Progress: In its Q2 earnings call, Veru highlighted that the combination of enobosarm and semaglutide showed significant results in the Phase IIb QUALITY trial, with 44.3% of placebo patients experiencing over a 10% decline in physical function at 16 weeks, while the enobosarm 3 mg group achieved a 59.8% relative improvement, indicating strong market competitiveness for the therapy in older obese patients.
- Financial Performance: CFO Greco reported a net loss of $2.7 million, a significant improvement from the previous quarter's $7.9 million, with loss per share decreasing from $0.54 to $0.12, reflecting positive progress in cost control and operational efficiency.
- Clinical Trial Progress: Veru announced the enrollment of the first patient in the Phase IIb PLATEAU study on March 9, 2026, with an interim analysis expected in Q1 2027 at 36 weeks, further validating its therapeutic efficacy and market potential.
- Market Outlook: Management expressed optimism regarding FDA feedback, suggesting that achieving over 5% weight loss could support additional claims for function and bone density, demonstrating the company's strategic positioning and market outlook in obesity treatment.
See More
Veru Reports Q2 Earnings Beat Expectations
- Earnings Beat: Veru's Q2 GAAP EPS of -$0.13 exceeded market expectations by $0.15, indicating an improvement in financial performance despite still being in a loss position.
- Cash Position Improvement: As of March 31, 2026, the company's cash, cash equivalents, and restricted cash totaled $27.6 million, a significant increase from $15.8 million as of September 30, 2025, demonstrating positive progress in cash management.
- Investor Engagement: Veru presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, drawing investor interest that could pave the way for future financing and partnership opportunities.
- Market Rating Dynamics: Seeking Alpha's Quant Rating on Veru reflects mixed market sentiment regarding its future performance, indicating a cautiously optimistic outlook among investors regarding the company's potential growth.
See More
Veru Reports Q2 Financials and Clinical Trial Updates
- Clinical Trial Progress: Veru's Phase 2b PLATEAU clinical trial is actively enrolling and is on track for an interim analysis in Q1 2027, aiming to evaluate the effects of enobosarm combined with semaglutide on older obese patients, potentially laying the groundwork for future weight loss treatment options.
- Improved Financial Performance: In Q2 of fiscal 2026, Veru reported a decrease in R&D expenses to $3.1 million from $3.9 million year-over-year, demonstrating effective cost control, while operating losses narrowed from $8.1 million to $7.2 million, indicating gradual financial improvement.
- Strong Cash Position: As of March 31, 2026, Veru's cash and cash equivalents reached $27.6 million, a significant increase from $15.8 million as of September 30, 2025, reflecting robust financial management and operational support.
- Positive Future Outlook: With the advancement of the Phase 2b PLATEAU trial, Veru anticipates releasing final clinical data in Q4 2027, and if results are favorable, this could enhance market acceptance and sales potential of its weight loss drugs, further strengthening the company's competitive position in the biopharmaceutical sector.
See More
Veru Scheduled to Announce Q2 Earnings on May 13
- Earnings Announcement: Veru is set to announce its Q2 earnings on May 13 before the market opens, with investors keenly awaiting insights into its financial performance amid current economic conditions.
- EPS Expectations: The consensus EPS estimate stands at -$0.29, indicating challenges in profitability that could impact investor confidence and stock performance.
- Forecast Revisions: Over the past three months, Veru's EPS estimates have seen two upward revisions with no downward adjustments, reflecting a cautiously optimistic market outlook that may provide some support for the stock price.
- Conference Presentation: Veru will also present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which could enhance its visibility among investors and potentially attract more interest and investment.
See More
Veru Inc. to Host Q2 2026 Financial Results Conference Call
- Conference Call Announcement: Veru Inc. will host a conference call on May 13, 2026, at 8:00 a.m. ET to discuss its Q2 2026 financial results and business updates, which is expected to positively influence investor confidence.
- Clinical Trial Progress: The Phase 2b PLATEAU clinical trial is currently enrolling approximately 200 older patients with obesity, aiming to evaluate the effects of enobosarm in combination with GLP-1 RA, and successful outcomes could enhance the company's market position in obesity treatment.
- Focus on Drug Development: Enobosarm is being developed as a next-generation drug to improve weight management outcomes when used with GLP-1 RA, and positive clinical trial results could lay the groundwork for future product line expansions.
- Future Data Expectations: An interim analysis of the PLATEAU trial is expected to be completed in Q1 2027, with final data anticipated in Q4 2027, and successful results could significantly boost Veru's stock price and market recognition.
See More
Veru Partners with Novo Nordisk for Phase 2b PLATEAU Study
- Clinical Trial Partnership: Veru announced it will sponsor the Phase 2b PLATEAU study, with Novo Nordisk providing Wegovy at no cost, significantly enhancing Veru's market position in obesity treatment.
- Stock Surge: Following the announcement of the clinical supply agreement with Novo Nordisk, Veru's stock soared over 160% in Thursday morning trading, reflecting strong investor confidence in its new drug enobosarm.
- Global Development Rights Retained: Veru stated in a filing with the SEC that it will retain full global development and commercialization rights to enobosarm, laying a solid foundation for future market promotion.
- Market Validation: Canaccord views this partnership as a significant milestone for Veru, indicating strong market interest in enobosarm and anticipating it could emerge as a key differentiator in obesity treatment.
See More
Veru Inc. Q2 Fiscal 2026 Earnings Call Insights
- R&D Progress: In its Q2 earnings call, Veru highlighted that the combination of enobosarm and semaglutide showed significant results in the Phase IIb QUALITY trial, with 44.3% of placebo patients experiencing over a 10% decline in physical function at 16 weeks, while the enobosarm 3 mg group achieved a 59.8% relative improvement, indicating strong market competitiveness for the therapy in older obese patients.
- Financial Performance: CFO Greco reported a net loss of $2.7 million, a significant improvement from the previous quarter's $7.9 million, with loss per share decreasing from $0.54 to $0.12, reflecting positive progress in cost control and operational efficiency.
- Clinical Trial Progress: Veru announced the enrollment of the first patient in the Phase IIb PLATEAU study on March 9, 2026, with an interim analysis expected in Q1 2027 at 36 weeks, further validating its therapeutic efficacy and market potential.
- Market Outlook: Management expressed optimism regarding FDA feedback, suggesting that achieving over 5% weight loss could support additional claims for function and bone density, demonstrating the company's strategic positioning and market outlook in obesity treatment.
See More
Veru Reports Q2 Earnings Beat Expectations
- Earnings Beat: Veru's Q2 GAAP EPS of -$0.13 exceeded market expectations by $0.15, indicating an improvement in financial performance despite still being in a loss position.
- Cash Position Improvement: As of March 31, 2026, the company's cash, cash equivalents, and restricted cash totaled $27.6 million, a significant increase from $15.8 million as of September 30, 2025, demonstrating positive progress in cash management.
- Investor Engagement: Veru presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, drawing investor interest that could pave the way for future financing and partnership opportunities.
- Market Rating Dynamics: Seeking Alpha's Quant Rating on Veru reflects mixed market sentiment regarding its future performance, indicating a cautiously optimistic outlook among investors regarding the company's potential growth.
See More
Veru Reports Q2 Financials and Clinical Trial Updates
- Clinical Trial Progress: Veru's Phase 2b PLATEAU clinical trial is actively enrolling and is on track for an interim analysis in Q1 2027, aiming to evaluate the effects of enobosarm combined with semaglutide on older obese patients, potentially laying the groundwork for future weight loss treatment options.
- Improved Financial Performance: In Q2 of fiscal 2026, Veru reported a decrease in R&D expenses to $3.1 million from $3.9 million year-over-year, demonstrating effective cost control, while operating losses narrowed from $8.1 million to $7.2 million, indicating gradual financial improvement.
- Strong Cash Position: As of March 31, 2026, Veru's cash and cash equivalents reached $27.6 million, a significant increase from $15.8 million as of September 30, 2025, reflecting robust financial management and operational support.
- Positive Future Outlook: With the advancement of the Phase 2b PLATEAU trial, Veru anticipates releasing final clinical data in Q4 2027, and if results are favorable, this could enhance market acceptance and sales potential of its weight loss drugs, further strengthening the company's competitive position in the biopharmaceutical sector.
See More
Veru Scheduled to Announce Q2 Earnings on May 13
- Earnings Announcement: Veru is set to announce its Q2 earnings on May 13 before the market opens, with investors keenly awaiting insights into its financial performance amid current economic conditions.
- EPS Expectations: The consensus EPS estimate stands at -$0.29, indicating challenges in profitability that could impact investor confidence and stock performance.
- Forecast Revisions: Over the past three months, Veru's EPS estimates have seen two upward revisions with no downward adjustments, reflecting a cautiously optimistic market outlook that may provide some support for the stock price.
- Conference Presentation: Veru will also present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which could enhance its visibility among investors and potentially attract more interest and investment.
See More
Veru Inc. to Host Q2 2026 Financial Results Conference Call
- Conference Call Announcement: Veru Inc. will host a conference call on May 13, 2026, at 8:00 a.m. ET to discuss its Q2 2026 financial results and business updates, which is expected to positively influence investor confidence.
- Clinical Trial Progress: The Phase 2b PLATEAU clinical trial is currently enrolling approximately 200 older patients with obesity, aiming to evaluate the effects of enobosarm in combination with GLP-1 RA, and successful outcomes could enhance the company's market position in obesity treatment.
- Focus on Drug Development: Enobosarm is being developed as a next-generation drug to improve weight management outcomes when used with GLP-1 RA, and positive clinical trial results could lay the groundwork for future product line expansions.
- Future Data Expectations: An interim analysis of the PLATEAU trial is expected to be completed in Q1 2027, with final data anticipated in Q4 2027, and successful results could significantly boost Veru's stock price and market recognition.
See More
